Literature DB >> 29933898

(R)-(+)-pulegone suppresses allergic and inflammation responses on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice model.

You Yeon Choi1, Mi Hye Kim1, Haesu Lee1, Si Yeon Jo1, Woong Mo Yang2.   

Abstract

BACKGROUND: (R)-(+)-pulegone (PLG), a biotransformation of monoterpene ketones, is one of essential oils of Labiatae family. Although PLG was reported to have anti-inflammatory and anti-histamine effects, the therapeutic effects of PLG on atopic dermatitis (AD) have not been reported yet.
OBJECTIVE: This study investigated the anti-AD effects and underlying mechanisms of PLG in AD-induced mice.
METHODS: BALB/c male mice were challenged with 2, 4-dinitrochlorobenzene (DNCB, 1%) to induce AD. After 4 days of rest, PLG (0.1, 1 and 10 μM) were topically applied to dorsal skin for 2 weeks with secondary elicitation using 0.5% DNCB. Histological changes were identified by H&E staining and mast cells were evaluated by toluidine blue staining. Pro-inflammatory cytokines and serum IgE levels were analyzed by ELISA. Inflammatory mediators were measured by western blotting assay.
RESULTS: Topical treatment with PLG significantly suppressed skin thickness and scratching behavior compared with control group. Expression of nerve growth factor was also decreased by PLG treatment. PLG administration decreased serum IgE levels and the number of mast cells in mice model of DNCB-induced AD. The levels of IL-4, IFN-γ, IL-6, TNF-α and IL-1β in dorsal skin of PLG-treated group were lower than those in the control group. PLG inhibited the phosphorylation of MAPKs, as well as IκBα degradation and NF-κB activation.
CONCLUSIONS: PLG attenuated the symptoms of AD by suppressing cytokines production, the phosphorylation of MAPKs and the activation of NF-κB signaling. These data suggest that PLG may be an effective natural compound for the treatment of inflammatory skin diseases.
Copyright © 2018 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (R)-(+)-pulegone; 2,4-dinitrochlorobenzene; Allergy; Atopic dermatitis; Inflammation

Mesh:

Substances:

Year:  2018        PMID: 29933898     DOI: 10.1016/j.jdermsci.2018.06.002

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  6 in total

1.  Management of Atopic Dermatitis Via Oral and Topical Administration of Herbs in Murine Model: A Systematic Review.

Authors:  Vivi Nur Khalieda Mohd Kasim; Siti Mahirah Noble; Kong Yen Liew; Ji Wei Tan; Daud Ahmad Israf; Chau Ling Tham
Journal:  Front Pharmacol       Date:  2022-05-24       Impact factor: 5.988

2.  Standardised comparison of limonene-derived monoterpenes identifies structural determinants of anti-inflammatory activity.

Authors:  Cátia Sousa; Alcino Jorge Leitão; Bruno Miguel Neves; Fernando Judas; Carlos Cavaleiro; Alexandrina Ferreira Mendes
Journal:  Sci Rep       Date:  2020-04-29       Impact factor: 4.379

3.  The Suppressive Effect of Mamiran Cream on Atopic Dermatitis-Like Skin Lesions In Vivo.

Authors:  Kailibinuer Aierken; Yuqing Luo; Maitinuer Maiwulanjiang; Tao Wu; H A Aisa
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-30       Impact factor: 2.629

4.  Anti-Hyperalgesic Properties of Menthol and Pulegone.

Authors:  Louis Hilfiger; Zélie Triaux; Christophe Marcic; Eléa Héberlé; Fathi Emhemmed; Pascal Darbon; Eric Marchioni; Hugues Petitjean; Alexandre Charlet
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

5.  Circadian Pharmacological Effects of Paeoniflorin on Mice With Urticaria-like Lesions.

Authors:  Li Peng; Lijuan Wen; Jie Zhang; Xiaotong Zhang; Qin Wei; Jing Guo; Jinhao Zeng
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

Review 6.  Post-Translational Modifications in Atopic Dermatitis: Current Research and Clinical Relevance.

Authors:  Xin Ma; Yi Ru; Ying Luo; Le Kuai; Qi-Long Chen; Yun Bai; Ye-Qiang Liu; Jia Chen; Yue Luo; Jian-Kun Song; Mi Zhou; Bin Li
Journal:  Front Cell Dev Biol       Date:  2022-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.